Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients

Journal of the National Cancer Institute

Volumn 98, Issue 7, 2006, Pages 441-450

  Khuri, Fadlo R ^a,g   Lee, J Jack ^b   Lippman, Scott M ^b,f   Kim, Edward S ^b   Cooper, Jay S ^c,g   Benner, Steven E ^h,m   Winn, Rodger ^g,j,m,n   Pajak, Thomas F ^g   Williams, Brendell ^b   Shenouda, George ^g,k   Hodson, Ian ^e,g   Fu, Karen ^d,g   Shin, Dong M ^a,g   Vokes, Everett E ^i,l   Feng, Lei ^b   Goepfert, Helmuth ^b   Hong, Waun Ki ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f Southwest Oncology Group   (United States)

^g RADIATION THERAPY ONCOLOGY GROUP   (United States)

^h PROTEIN DESIGN LABS INC   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j NATIONAL QUALITY FORUM   (United States)

^k MCGILL UNIVERSITY   (Canada)

^l Cancer and Leukemia Group B   (United States)

^m Community Clinical Oncology Programs ^*  (United States)

ⁿ Texas Community Oncology Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; PLACEBO; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEILITIS; CIGARETTE SMOKING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; KAPLAN MEIER METHOD; LARYNX TUMOR; LOW DRUG DOSE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MOUTH TUMOR; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PAIN; PATIENT MONITORING; PHARYNX TUMOR; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SECOND CANCER; SENSORY DYSFUNCTION; SKIN TOXICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEAD AND NECK TUMOR; METASTASIS; PATHOLOGY; PATIENT SELECTION; RISK; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT FAILURE;

AGED; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; ISOTRETINOIN; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 33645735216     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj091     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. American Cancer Society. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Parkin M, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Khuri FR, Kim ES. Primary head and neck cancer. In: Clinical hematology and oncology. Furie B, Cassileth PA, Atkins MB, Mayer RJ (eds). Philadelphia (PA): Elsevier; 2003. p. 999-1011.
4. Stewart BW, Kleihues P, eds. World cancer report: Head and neck cancer. Lyon (France): IARC Press; 2003. p. 232-6.
5. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1984;110:564-5.
6. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on RTOG experience. Intl J Radiat Oncol Biol Phys 1989;17:449-56.
7. Licciardello JT, Spitz MR, Hong WK. Multiple primary cancers in patients with cancer of the head and neck; second cancer of the head and neck, esophagus and lung. Intl J Radiat Oncol Biol Phys 1989;17:467-76.
8. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
9. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
10. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
11. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isoretinoin in squamous cell carcinoma of the head and neck: Long term follow up. J Natl Cancer Inst 1994;86:140-1.
12. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y, et al. Prevention of second primary tumors with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 1994;30A:767-72.
13. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216-22.
14. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-9.
15. National Cancer Institute. Common toxicity criteria. 1999. Available at: http://ctep.cancer.gov/forms/ctcv2nom-4-30-99-final3.pdf.
16. Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and statistical study. Am J Cancer 1932;16:1358-414.
17. Grambsch PM, Therneau TM. Proportional hazards test and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
18. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: A simulation study. Stat Med 1999; 18:3075-88.
19. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
20. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, et al. Combined interferon-alpha, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: Novel bioadjuvant phase II trial. J Clin Oncol 2001;19:3010-7.
21. Seixas-Silva JA, Richards TJ, Khuri FR, Wieand S, Kim ES, Murphy B, et al. Phase II bioadjuvant study of interferon-, 13-cis-retinoic acid, and alphatocopherol in locally advanced squamous cell carcinoma of the head and neck: Long-term follow-up. Arch Otolaryngol Head Neck Surg 2005; 131: 304-7.
22. Russo A, Crosignani P, Berrino F. Tobacco smoking, alcohol drinking and dietary factors as determinants of new primaries among male laryngeal cancer patients: A case-cohort study. Tumori 1996;82:519-25.
23. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997;89:1782-8.
24. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87:1530-7.
25. Richardson GE, Tucker MA, Venzon DJ, Linnoila RI, Phelps R, Phares JC, et al. Smoking cessation after successful treatment of small-call lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383-90.
26. Silverman S Jr, Gorsky M, Greenspan D. Tobacco usage in patients with head and neck carcinomas: A follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 1983;106:33-5.
27. Khuri FR, Lotan R, Kemp BL, Lippman SM, Feng L, Lee JJ, et al. Retinoic acid receptor (RARbeta) as a prognostic indicator in stage I non-small cell lung cancer. J Clin Oncol 2000;18:2798-804.
28. Kim JS, Lee H, Kim H, Shim YM, Han J, Park J, et al. Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. J Clin Oncol 2004;22: 3435-7.
29. Khuri FR, Lotan R. Retinoids in lung cancer: Friend, foe, or fellow traveler? J Clin Oncol 2004;22:3435-7.
30. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996;56:2488-92.
31. Califano J, Westra W, Meninger G, Corio R, Koch WM, Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000;6:347-52.
32. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000;92:977-86.
33. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:2626-37.
34. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51.
35. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaiah K. Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract. Ann N Y Acad Sci 2001;952:109-15.
36. Khuri FR, Nemunaitis J, Ganly I, Arsenau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
37. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003;21:4546-52.
38. Klass C, Shin DM, Khuri FR. New directions in chemoprevention of head and neck cancer. American Society of Clinical Oncology Education Book. Alexandria (VA): ASCO; 2005. p. 454-60.
39. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:5930-9.
40. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand H, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005; 11:6261-9.